INTRODUCTION AND OBJECTIVES: Systemic inflammation is a common host reaction to cancer progression. Serum level of buttyrylcholinesterase (BChE) have been reported to reflect the presence of inflammation and other clinical conditions. BChE is an alphaglycoprotein found in the nervous system and liver. Its serum level is reduced in many clinical conditions, such as liver damage, injury, infection, and malignant disease. We retrospectively evaluated the potential prognostic significance of buttyrylcholinesterase before chemotherapy as an independent predictor of overall survival in patients with advanced upper-tract urothelial cancer.
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METHODS: We treated seventy-four patients (52 men and 22 women) with advanced upper-tract urothelial cancer (UTUC) at our clinic between August 2004 and December 2015. The average age was 69.3 (43e89), and average eGFR was 50.5 (11.6e99.3) ml/minute/1.73m2. Mean observation period was 24.0 (3e96) months. Levels of serum BChE (normal range 168-470 U/L) were measured 1 week before chemotherapy. The average serum level of BChE were 240.6 U/L (53-509). The patients received 2 courses of GCarbo consisted of 800mg/m2 gemcitabine on days 1, 8, and 15 and carboplatin (AUC 4) on day 2. If this regimen was effective, another 2 courses of GCcarbo was performed. If this regimen did not induce any tumor size reduction, we switched to 2 courses of GCarboD (D; 70mg/m2) treatment as second-line treatment.
RESULTS: GCarbo regimen yielded 5 cases (6.8%) of CR, 32 (43.2%) of PR, and the average duration of response of 11.4 (2e29) months. GCarboD treatment was administered in 21 cases, and yielded 2 (9.5%) PR and a duration of response was 31.5(7-50) months. 
INTRODUCTION AND OBJECTIVES:
The precise prediction of perioperative change in renal function would enable the appropriate management including perioperative systemic chemotherapy for patients with upper tract urothelial carcinoma (UTUC). The renal cortex enhancement in CT could reflect renal function. We have reported the usefulness of renal cortex enhancement to predict residual single kidney function after nephroureterectomy (NU) [AUA 2015] . The predictive ability of renal cortex enhancement in CT was evaluated in comparison with that of nuclear renography.
METHODS: Forty-seven patients with UTUC in whom both dynamic CT and Tc-99m diethylenetriamine pentaacetic acid renography were performed before NU were subjects of this study. Pre-and postoperative estimated glomerular filtration rates (eGFRs) were calculated using serum creatinine measured before and 1-3 months after NU, respectively. Renal cortex radiodensity was measured in Hounsfield units (HU) from a round region of interest placed over the highest enhancing area on corticomedullary images. CT-based split renal function (SRF) of the intact contralateral kidney was calculated by splitting pre-eGFR: pre-eGFR Â percent of total HU. The same formula was used for nuclear SRF. The correlations between observed and calculated post-eGFR using CT and nuclear renography were assessed with a calibration plot.
RESULTS: The median pre-eGFR was 77 (range: 41-124) ml/ min/1.73 m 2 , and decreased to 53 (27-89) after NU. The median percent of total HU for the contralateral kidney was 52% (48-68), and that of the total nuclear SRF was 56% (43-100). CT-based SRF showed linear correlation with the observed post-eGFR (r ¼ 0.80), which was equivalent to the nuclear SRF (r ¼ 0.78). From the conversion factors derived from a linear regression, an updated prediction formula was developed by parallel translation, adding 11.7 to the CT-based SRF and 8.8 to the nuclear SRF. The calibration plot in which the observed post-eGFR was plotted against each updated SRF showed equally good agreement ( Fig.) .
CONCLUSIONS: The predictive ability of CT enhancement for postoperative renal function is feasible and comparable to that of renography. This CT model could be useful in clinical practice because CT is an essential diagnostic tool for patients with UTUC. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e951
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